Lead Product(s) : Lixudebart
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : Morningside Ventures
Deal Size : $67.0 million
Deal Type : Series B Financing
Alentis Therapeutics Raises USD 67 Million in Series B Financing
Details : Alentis’ lead molecules ALE.F02 and ALE.C04 are highly selective anti-Claudin-1 mAb that recognize pathological overexpressed and conformation-dependent Claudin-1 epitopes in fibrotic disease and cancer.
Product Name : ALE.F02
Product Type : Antibody
Upfront Cash : Undisclosed
June 15, 2021
Lead Product(s) : Lixudebart
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : Morningside Ventures
Deal Size : $67.0 million
Deal Type : Series B Financing
Lead Product(s) : CM5480
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : CalciMedica
Deal Size : Undisclosed
Deal Type : Collaboration
Details : CalciMedica to use EpiPharma’s state-of-the-art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate the discovery and development of CalciMedica’s CRAC channel inhibitor novel drug pipeline.
Product Name : CM5480
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 21, 2020
Lead Product(s) : CM5480
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : CalciMedica
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Efimosfermin Alpha
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : Boston Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Boston Pharmaceuticals Licenses NASH Development Candidate from Novartis
Details : Under the terms of the agreement, Boston Pharmaceuticals will license worldwide development and commercial rights to the drug candidate BOS-580, for the treatment of Non-Alcoholic Steatohepatitis (NASH) from Novartis.
Product Name : BOS-580
Product Type : Protein
Upfront Cash : Undisclosed
January 09, 2020
Lead Product(s) : Efimosfermin Alpha
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : Boston Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement